

Publikationsliste Patrick Imesch

Originalarbeiten:

1. Attitudes and perceptions of affected women towards endocrine endometriosis therapy: an international survey based on free-word association networks.
Thurnherr N, Burla L, Metzler JM, File B, **Imesch P**.
Hum Reprod. 2023 Oct 25:dead221. doi: 10.1093/humrep/dead221. Online ahead of print.
Impact factor: 6.353 (2021)
2. Effects of vitamin D supplementation in endometriosis: a systematic review.
Kalaitzopoulos DR, Samartzis N, Daniilidis A, Leeners B, Makieva S, Nirgianakis K, Dedes I, Metzler JM, **Imesch P**, Lempesis IG.
Reprod Biol Endocrinol. 2022 Dec 28;20(1):176. doi: 10.1186/s12958-022-01051-9.
Impact factor: 4.982 (2021)
3. Endometriosis features and dienogest tolerability in women with depression: a case-control study.
Dietrich H, Knobel C, Portmann L, Metzler J, Muendane A, Niggli A, Neumeier MS, **Imesch P**, Merki-Feld GS.
Eur J Contracept Reprod Health Care. 2023 May 3:1-7. doi: 10.1080/13625187.2023.2199899. Online ahead of print.
4. Comparison of male and female perspective in couples involved in sexual relationships and facing endometriosis.
Helfenstein F, Kohl Schwartz AS, **Imesch P**, Rauchfuss M, Wölfli MM, Haeblerlin F, von Orelli S, Leeners B. Sex Med. 2023 May 29;11(2):qfad013. doi: 10.1093/sexmed/qfad013. eCollection 2023 Apr.
5. Endometriosis Features in Women With and Without Migraine.
Neumeier MS, Pohl H, Dietrich H, Knobel C, Portmann L, Metzler J, **Imesch P**, Merki-Feld GS. J Womens Health (Larchmt). 2023 Mar 10. doi: 10.1089/jwh.2022.0359. Online ahead of print
Impact factor: 3.017 (2021)
6. The immunohistochemical expression of GPER and classical sex hormone receptors differs in adenomyosis and eutopic endometrium.
Samartzis N, Kalaitzopoulos DR, Noske A, Ihnenfeld I, Hutmacher J, **Imesch P**, Samartzis EP.
J Reprod Immunol. 2023 Jan 6;156:103795. doi: 10.1016/j.jri.2023.103795.
Impact factor: 3.993 (2021)
7. Judging Urgency in 343 Ectopic Pregnancies Prior to Surgery - The Importance of Transvaginal Sonographic Diagnosis of Intraabdominal Free Blood.
Pape J, Bajka A, Seifert B, Asmis L, **Imesch P**, Metzler J, Burkhardt T, Condous G, Samartzis EP, Bajka M.
Ultraschall Med. 2023 Jan 19. doi: 10.1055/a-1967-2134.
Impact factor: 5.445 (2021)

8. Living with endometriosis: Comorbid pain disorders, characteristics of pain and relevance for daily life.
Leuenberger J, Kohl Schwartz AS, Geraedts K, Haeberlin F, Eberhard M, von Orellie S, **Imesch P**, Leeners B.
Eur J Pain. 2022 Feb 19. doi: 10.1002/ejp.1926. Online ahead of print
Impact factor: 3.651 (2021)
9. Examining the Influence on Perceptions of Endometriosis via Analysis of Social Media Posts: Cross-sectional Study.
Metzler JM, Kalaitzopoulos DR, Burla L, Schaer G, **Imesch P**.
JMIR Form Res. 2022 Mar 18;6(3):e31135. doi: 10.2196/31135.
10. Popularity of endocrine endometriosis drugs and limited alternatives in the present and foreseeable future: A survey among 1420 affected women.
Burla L, Kalaitzopoulos DR, Metzler JM, Scheiner D, **Imesch P**.
Eur J Obstet Gynecol Reprod Biol. 2021 May 27;262:232-238. doi:
10.1016/j.ejogrb.2021.05.040. Online ahead of print.
Impact factor: 2.831 (2021)
11. The Predictive Value of Decisive and Soft Ultrasound Criteria for Ectopic Pregnancy Identification in 321 Preoperative Cases.
Pape J, Bajka A, Strutas D, Burkhardt T, **Imesch P**, Fink D, Samartzis EP, Bajka M.
Ultraschall Med. 2021 May 6. doi: 10.1055/a-1487-5030. Online ahead of print.
Impact factor: 5.445 (2021)
12. Structured manual for MRI assessment of deep infiltrating endometriosis using the ENZIAN classification.
Burla L, Scheiner D, Hötker AM, Meier A, Fink D, Boss A, **Imesch P**.
Arch Gynecol Obstet. 2020 Nov 22. doi: 10.1007/s00404-020-05892-w.
Impact factor: 2.493 (2021)
13. Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
Julian Matthias Metzler, Daniel Fink and **Patrick Imesch**
Appl. Sci. 2021, 11(1), 222; <https://doi.org/10.3390/app11010222> - 28 Dec 2020
Impact factor: 2.838 (2021)
14. Sexual Satisfaction and Frequency of Orgasm in Women With Chronic Pelvic Pain due to Endometriosis.
Hämmerli S, Kohl-Schwartz A, **Imesch P**, Rauchfuss M, Wölfler MM, Häberlin F, von Orelli S, Leeners B.
J Sex Med. 2020 Oct 5:S1743-6095(20)30920-6. doi: 10.1016/j.jsxm.2020.09.001.
Impact factor: 3.937 (2021)
15. Qualitative and quantitative aspects of sex life in the context of endometriosis: A multicentre case control study.
Bernays V, Schwartz AK, Geraedts K, Rauchfuss M, Wölfler MM, Haeberlin F, von Orelli S, Eberhard M, Imthurn B, Fink D, **Imesch P**, Leeners B.
Reprod Biomed Online. 2020 Feb;40(2):296-304.
Impact factor: 4.567 (2021)

16. Doxycycline reduces MMP-2 activity and inhibits invasion of 12Z epithelial endometriotic cells as well as MMP-2 and -9 activity in primary endometriotic stromal cells in vitro.
Samartzis EP, Fink D, Stucki M, **Imesch P**.
Reprod Biol Endocrinol. 2019 Apr 13;17(1):38. doi: 10.1186/s12958-019-0481-z.
Impact factor: 4.982 (2021)
17. The ENZIAN score as a preoperative MRI-based classification instrument for deep infiltrating endometriosis.
Burla L, Scheiner D, Samartzis EP, Seidel S, Eberhard M, Fink D, Boss A, **Imesch P**.
Arch Gynecol Obstet. 2019 Apr 12. doi: 10.1007/s00404-019-05157-1.
Impact factor: 2.493 (2021)
18. Does endometriosis affect professional life? A matched case-control study in Switzerland, Germany and Austria
Marita Lina Sperschneider, Michael P Hengartner, Alexandra Kohl-Schwartz, Kirsten Geraedts, Martina Rauchfuss, Monika Martina Woelfler, Felix Haerberlin, Stephanie von Orelli, Markus Eberhard, Franziska Maurer, Bruno Imthurn, **Patrick Imesch**, Brigitte Leeners
BMJ Open Jan 2019, 9 (1) bmjopen-2017-019570; DOI: 10.1136/bmjopen-2017-019570
Impact factor: 3.017 (2021)
19. The use of home remedies and complementary health approaches in endometriosis.
Schwartz ASK, Gross E, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, von Orelli S, Eberhard M, **Imesch P**, Imthurn B, Leeners B.
Reprod Biomed Online. 2019 Feb;38(2):260-271.
Impact factor: 4.567 (2021)
20. Satisfaction with medical support in women with endometriosis.
Lukas I, Kohl-Schwartz A, Geraedts K, Rauchfuss M, Wölfler MM, Häberlin F, von Orelli S, Eberhard M, Imthurn B, **Imesch P**, Leeners B.
PLoS One. 2018 Nov 29;13(11):e0208023.
Impact factor: 3.752 (2021)
21. Fatigue - a symptom in endometriosis.
Ramin-Wright A, Kohl Schwartz AS, Geraedts K, Rauchfuss M, Wölfler MM, Haerberlin F, von Orelli S, Eberhard M, Imthurn B, **Imesch P**, Fink D, Leeners B.
Hum Reprod. 2018 Jun 26. doi: 10.1093/humrep/dey115. [Epub ahead of print]
Impact factor: 6.353 (2021)
22. Maltreatment during childhood: a risk factor for the development of endometriosis?
Liebermann C, Kohl Schwartz AS, Charpidou T, Geraedts K, Rauchfuss M, Wölfler M, von Orelli S, Häberlin F, Eberhard M, **Imesch P**, Imthurn B, Leeners B.
Hum Reprod. 2018 Jun 26. doi: 10.1093/humrep/dey111. [Epub ahead of print]
Impact factor: 6.353 (2021)
23. Does Endometriosis Affect Sexual Activity and Satisfaction of the Man Partner? A Comparison of Partners From Women Diagnosed With Endometriosis and Controls.

Hämmerli S, Kohl Schwartz AS, Geraedts K, **Imesch P**, Rauchfuss M, Wölfler MM, Haeberlin F, von Orelli S, Eberhard M, Imthurn B, Leeners B.
J Sex Med. 2018 Apr 26. pii: S1743-6095(18)30271-6. D 10.1016/j.jsxm.2018.03.087.
Impact factor: 3.937 (2021)

24. Endometriosis, especially mild disease: a risk factor for miscarriages.
Kohl Schwartz AS, Wölfler MM, Mitter V, Rauchfuss M, Haeberlin F, Eberhard M, von Orelli S, Imthurn B, **Imesch P**, Fink D, Leeners B.
Fertil Steril. 2017 Oct 24. pii: S0015-0282(17)31747-8. doi:
Impact factor: 7.490 (2021)
25. Comparison of quartz vials with polypropylene vials for rapid cryopreservation of human ovarian tissue.
Scheiner D, Bracone G, **Imesch P**, Fink D, Hehl J, Imthurn B.
J Ovarian Res. 2016 Sep 26;9(1):59.
Impact factor: 5.506 (2021)
26. Pelvic Exenterations for Advanced and Recurrent Endometrial Cancer: Clinical Outcomes of 40 Patients.
Schmidt AM, **Imesch P**, Fink D, Egger H.
Int J Gynecol Cancer. 2016 Mar 3. [Epub ahead of print]
Impact factor: 4.678 (2021)
27. The estrogen metabolites 2-methoxyestradiol and 2-hydroxyestradiol inhibit endometriotic cell proliferation in estrogen-receptor-independent manner.
Samartzis EP, **Imesch P**, Twiehaus A, Dubey RK, Leeners B.
Gynecol Endocrinol. 2016 Jan 22:1-5.
Impact factor: 2.277 (2021)
28. Use of inpatient rehabilitation for cancer patients in Switzerland: who undergoes cancer rehabilitation?
Ture M, Barth J, Angst F, Aeschlimann A, Schnyder U, Zerkiebel N, Perseus J, Renner C, **Imesch P**, Fuchs B, Huber GF, Walt H, Martin-Soelch C, Jenewein J.
Swiss Med Wkly. 2015 Dec 4;145:w14214.
Impact factor: 4.203 (2021)
29. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, **Imesch P**.
Oncotarget. 2014 Jul 30;5(14):5295-303
Impact factor 5.168 (2016)
30. Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro.
Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, **Imesch P**, Ikenberg K, Moch H, Fink D, Stucki M, Dedes KJ.
PLoS One. 2014 Jun 13;9(6):e100041.
Impact factor: 3.752 (2021)
31. Eleftherios P. Samartzis, Aurelia Noske, Alexander Meisel, Zsuzsanna Varga, Daniel Fink, **Patrick Imesch**
The G protein-coupled estrogen receptor (GPER) is expressed in two different subcellular localizations reflecting distinct tumor properties in breast cancer

PLoS One. 2014 Jan 8;9(1):e83296.
Impact factor: 3.752 (2021)

32. Fehr MK, Baumann M, Mueller M, Fink D, Heinzl S, **Imesch P**, Dedes K.
Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia.
J Gynecol Oncol. 2013 Jul;24(3):236-41
Impact factor: 4.756 (2021)
33. **Imesch P**, Samartzis EP, Dedes KJ, Fink D, Fedier A.
Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells.
Fertil Steril. 2013 Sep;100(3):770-6.
Impact factor: 7.490 (2021)
34. **Imesch P.**, Scheiner D., Szabo E., Fink D., Fedier A.
Conjugates of cytochrome c and antennapedia peptide activate apoptosis and inhibit proliferation of HeLa cancer cells
Exp Ther Med. 2013 Sep;6(3):786-790.
Impact factor: 2.751 (2021)
35. Samartzis EP, Noske A, Samartzis N, Fink D, **Imesch P.**
The Expression of Histone Deacetylase 1, But Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis.
Reprod Sci. 2013 Dec;20(12):1416-22.
Impact factor: 2.924 (2021)
36. **Imesch P**, Scheiner D, Xie M, Fink D, Macas E, Dubey R, Imthurn B.
Developmental potential of human oocytes matured in vitro followed by vitrification and activation.
J Ovarian Res. 2013 Apr 18;6(1):30.
Impact factor: 5.506 (2021)
37. **Imesch P**, Goerens A, Fink D, Fedier A.
MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly(A) polymerase inhibitor cordycepin (3'-deoxyadenosine) in vitro.
Oncol Lett. 2012 Feb;3(2):441-444.
Impact factor: 3.111 (2021)
38. Samartzis N, Samartzis E, Noske A, Fedier A, Dedes K, Caduff R, Fink D, **Imesch P.**
Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study.
Reprod Biol Endocrinol. 2012 Apr 20;10:30.
Impact factor: 4.982 (2021)
39. Schmidt AM, **Imesch P**, Fink D, Egger H.
Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer.
Gynecol Oncol. 2012 Jun;125(3):604-9.

Impact factor: 5.304 (2021)

40. Samartzis E, Samartzis N, Noske A, Fedier A, Caduff R, Dedes K, Fink D, **Imesch P**.
Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Mod Pathol. 2012 Jun;25(6):885-92.
Impact factor: 8.209 (2021)
41. Leimbacher B, Samartzis N, **Imesch P**, Dedes KJ, Fink D, Canonica C.
Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis.
Arch Gynecol Obstet. 2012 May;285(5):1441-5.
Impact factor: 2.493 (2021)
42. Samartzis N, **Imesch P**, Dedes KJ, Samartzis EP, Fedier A, Fink D, Caduff R, Fehr MK.
Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study.
BMC Cancer. 2011 Oct 26;11:463.
Impact factor: 4.638 (2021)
43. Schwager K, Bootz F, **Imesch P**, Kaspar M, Trachsel E, Neri D.
The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Hum Reprod. 2011 Sep;26(9):2344-52.
Impact factor: 6.353 (2021)
44. **Imesch P**, Samartzis EP, Schneider M, Fink D, Fedier A.
Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin.
Fertil Steril. 2011 Apr;95(5):1579-83.
Impact factor: 7.490 (2021)
45. **Imesch P**, Hornung R, Fink D, Fedier A.
Cordycepin (3'-deoxyadenosine), an inhibitor of mRNA polyadenylation, suppresses proliferation and activates apoptosis in human epithelial endometriotic cells in vitro.
Gynecol Obstet Invest. 2011;72(1):43-9.
Impact factor: 2.729 (2021)
46. **Imesch P**, Fink D, Fedier A.
Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
Fertil Steril. 2010 Dec;94(7):2838-42.
Impact factor: 7.490 (2021)
47. **Imesch P**, Dedes KJ, Furlato M, Fink D, Fedier A.
MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Int J Oncol. 2009 Sep;35(3):631-40.
Impact factor: 5.884 (2021)

48. Dedes KJ, Dedes I, **Imesch P**, von Bueren AO, Fink D, Fedier A.
Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Anticancer Drugs. 2009 Jun;20(5):321-33.
Impact factor: 1.869 (2017)
49. Dedes KJ, Szucs TD, **Imesch P**, Fedier A, Fehr MK, Fink D.
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
Ann Oncol. 2007 Sep;18(9):1493-9.
Impact factor: 51.769 (2021)
50. Fedier A, Dedes KJ, **Imesch P**, Von Bueren AO, Fink D.
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Int J Oncol. 2007 Sep;31(3):633-41.
Impact factor: 5.884 (2021)

Fallbeschreibungen (case reports)

1. **Patrick Imesch**, Daniel Fink
21-jährige Patientin mit Dysmenorrhoe und Dyspareunie
ELSEVIER CaseReports • Endometriose & Dienogest (Visanne®), S. 6-7, 2012
2. Ihnenfeld Arciénega I, **Imesch P**, Fink D, Dedes KJ.
Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.
Target Oncol. 2014 Dec 17. [Epub ahead of print
Impact factor: 4.864 (2021)
3. Limani-Gadiant N, Oertle D, **Imesch P**, Fink D
Geminigravidität mit kompletter Blasenmole nebst koexistierendem vitalen Fetus
Schweiz Med Forum 2016;16(22):472-473
4. Brun R, Hutmacher J, Fink D, **Imesch P**.
Erroneously Suspected Ovarian Cancer in a 38-Year-Old Woman with Pelvic Inflammatory Disease and Chlamydia.
Case Rep Obstet Gynecol. 2017;2017:2514613. doi: 10.1155/2017/2514613. Epub 2017 Dec 13.
5. Metzler JM, Schaer G, **Imesch P**.
First case of four spontaneously conceived successful pregnancies after fertility-sparing surgery for cervical cancer.
Clin Case Rep. 2021;00:e04534. <https://doi.org/10.1002/ccr3.4534>

Übersichtsarbeiten (Reviews)

1. Symptome und Management des Uterusdefekts nach Sectio
Betschart Cornelia, **Imesch Patrick**
Praxis Depesche No3, Jun 21, S. 46-49
2. Der chronische Unterbauchschmerz der Frau-Abklärung und Therapie
L. Burla, **P. Imesch**
Gynäkologische Praxis 48, 87–99 (2021)
3. Deep Infiltrating Endometriosis - a Systematic Approach to Diagnostics and Surgery Planning.
Burla L, Fink D, **Imesch P.**
Praxis (Bern 1994). 2020 Jul;109(9):725-730.
4. Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
Julian Matthias Metzler , Laurin Burla , Daniel Fink and **Patrick Imesch**
Int J Mol Sci. 2020 Jun 10;21(11):E4154. doi: 10.3390/ijms21114154.
Impact factor: 6.208 (2021)
5. Primary Peritoneal Serous Borderline Tumors as a Therapeutic Challenge: a Systematic Review of the Literature
Janna Pape, Eleftherios Pierre Samartzis, Daniel Fink & **Patrick Imesch**
SN Compr. Clin. Med. 2, 316–326 (2020).
6. Probleme der Narbendehiszenz nach Sectio
P. Imesch, D. Fink
Gynäkologische Praxis 2019, Band 45/2, S. 246-252
7. Hormonersatztherapie nach gynäkologischen Karzinomen
Krischer B.; Fink D.; **Imesch P.**
Leading Opinions Gynäkologie & Geburtshilfe 2019
8. Endometriose
Patrick Imesch
Hausarzt Praxis 2019; Vol. 14, Nr. 4
9. Endokrine Therapieoptionen nach gynäkologischen Karzinomen
Ioannis Dedes, **Patrick Imesch**, Daniel Fink
Schweizer Zeitschrift für Gynäkologie, Issue 4, 2018, Pages 10-15
10. Evolution der gynäkologisch-onkologischen Chirurgie
Imesch P.; Fink D.
Leading opinions 1/2018, S.13-15
11. Chirurgie der infiltrativ wachsenden Endometriose
Imesch P., Fink D.
Schweizer Zeitschrift für Gynäkologie, Issue 1, 2018, Pages 6-9

12. Endometriose und Sexualität, Symptomatik und Bewältigungsstrategien
BRIGITTE LEENERS, ALEXANDRA S. KOHL SCHWARTZ, KIRSTEN GERAEDTS, MONIKA WÖFLER, STEFANIE VON ORELLI, FELIX HÄBERLIN, MARKUS EBERHARD, **PATRICK IMESCH**, DANIEL FINK, BRUNO IMTHURN, MARTINA RAUCHFUSS
Schweizer Zeitschrift für Gynäkologie, Issue 1, 2018, Pages 15-19
13. Die Adenomyose
Hutmacher J., **Imesch P.**, Fink D.
Schweizer Zeitschrift für Gynäkologie, Issue 1, 2018, Pages 20-24
14. Endometriose-Update 2016.
Imesch P., Fink D.
Praxis (Bern 1994). 2016 Mar 2;105(5):253-8. doi: 10.1024/1661-8157/a002295.
15. ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
Eleftherios P. Samartzis, Aurelia Noske, Konstantin J. Dedes, Daniel Fink and **Patrick Imesch**
Int. J. Mol. Sci. 2013, 14(9), 18824-18849
Impact factor: 6.208 (2021)
16. Fertilitätserhaltende Therapien bei Ovarial- und Borderline-Tumoren
Patrick Imesch, Daniel Fink
Leading Opinions, Medizin für die Frau 2013/3 S. 20-22
17. Aftercare in gynecological oncology: Recommendations for the practice
[Nachsorge in der gynäkologischen Onkologie]
Patrick Imesch und Daniel Fink
Schweizer Zeitschrift für Gynäkologie. Vol. 17, Issue 5, 14 December 2012, Pages 6-9
18. Medikamentöse Therapie der Endometriose - Heutige hormonelle Ansätze
Patrick Imesch, Eleftherios P. Samartzis, Daniel Fink
ARS MEDICI 18; 2012 S. 934-937
19. Was bringt ein Screening beim Ovarial- und Korpus-Ca?
Patrick Imesch, Natalie Gabriel, Daniel Fink
Leading Opinions Medizin für die Frau 3/2012 S.28-30
20. Diagnostik und Therapie der Endometriose
Michael Mueller, Dr. Markus Eberhard, Christian De Geyter, Dr. Felix Häberlin, Michael K Hohl, **Patrick Imesch**, Christian Polli, Marc Possover, Katharina Schiessl, Jean-Marie Wenger, Dorothea Wunder
Frauenheilkunde aktuell 21/2/2012 S.28-34
21. Pathogenesis of endometriosis: Theories and mechanisms of the development of endometriosis [Pathogenese der Endometriose: Theorien und Mechanismen der Endometrioseentstehung]
Samartzis, E.P., **Imesch, P.**, Fink, D.
Schweizer Zeitschrift für Gynäkologie, Volume 17, Issue 3, 2012, Pages 6-10

22. Drug therapy of endometriosis: Today's hormonal and non-hormonal approaches
[Medikamentöse Therapie der Endometriose: Heutige hormonelle und nicht
hormonelle Ansätze]
Imesch, P., Samartzis, E.P., Fink, D.
Schweizer Zeitschrift für Gynäkologie, Volume 17, Issue 3, 2012, Pages 17-20
23. Prävalenz, Diagnostik und Therapie der Endometriose
Patrick Imesch, Eleftherios P. Samartzis, Daniel Fink
info@gynäkologie 03, 2012 S. 19-21
24. Cervical cancer
Ther Umsch. 2011 Oct;68(10):545-52.
Imesch P, Fink D.
25. Das Endometriumkarzinom, Epidemiologie, Präkanzerosen, Diagnostik, Therapie und
Nachsorge
Imesch P, Fink D.
Schweizer Zeitschrift für Onkologie, Ausgabe 05.08
26. Laparoscopic approach in endometrial cancer: current data and evidence
Imesch P, Dedes K, Fink D.
Gynakol Geburtshilfliche Rundsch. 2009;49(3):111-6.
27. Richtiges operatives Vorgehen bei unerfülltem Kinderwunsch
P. Imesch, D. Fink
Leading Opinions Zeitschrift für Gynäkologie und Geburtshilfe, Jahrgang 3 Sept.
2010 S. 34-36
28. Endometriose-eine epigenetische Erkrankung?
P.Imesch, E.P. Samartzis, D. Fink
Endometriose Aktuell, 2/2010, S. 2-4
29. Endometriose-eine epigenetische Erkrankung?
P.Imesch, E.P. Samartzis, D. Fink
Leading Opinions Zeitschrift für Gynäkologie und Geburtshilfe, Jahrgang 4 Feb. 2011
S. 2-4
30. Aktuelle Diagnostik und operative Therapie der Endometriose in der Praxis
P. Imesch, D. Fink
info@gynäkologie 3.2015 S. 18-20
31. Das Endometriumkarzinom: Diagnostik und Therapie.
Imesch Patrick; Fink Daniel (2013). Schweizer Zeitschrift für Onkologie, (4):2-6.

Publikationen als Mitarbeiter von Studienteams (study collaborators)

1. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Krop IE1, Kim SB2, González-Martín A3, LoRusso PM4, Ferrero JM5, Smitt M6, Yu R6, Leung AC6, Wildiers H7; TH3RESA study collaborators.
Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2.

2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Ceirbhail RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28

Buchkapitel:

1. **Patrick Imesch**, Mathias Fehr und Daniel Fink
Maligne epitheliale Tumoren des Corpus uteri (ausschliesslich des Karzinosarkomes)
In: Praxisbuch Gynäkologische Onkologie, pp 37-54, Springer, 4. Auflage
2. **Patrick Imesch**, Mathias Fehr und Daniel Fink
Karzinosarkome des Uterus (maligne Müller-Mischtumoren des Uterus, maligne mesodermale Mischtumoren, maligne gemischte mesenchymale Tumoren In:
Praxisbuch Gynäkologische Onkologie, pp 57-62, Springer, 4. Auflage
3. **Patrick Imesch**, Mathias Fehr und Daniel Fink
Maligne nichtepitheliale Tumoren des Corpus uteri (ausschliesslich des Karzinosarkomes) In: Praxisbuch Gynäkologische Onkologie, pp 65-70, Springer, 4. Auflage
4. **Patrick Imesch**, Daniel Fink
Mammakarzinom der alten Frau
In: Therapie des primären Mammakarzinoms, Kapitel 8.3. pp 132-136, Uni-Med Science, 1. Auflage
5. **Patrick Imesch**, Daniel Fink
Endometriumkarzinom
Hämatologie und Onkologie, pp 390-394, Thieme, 1. Auflage, 2016
6. **Patrick Imesch**, Daniel Fink
Zervixkarzinom
Hämatologie und Onkologie, pp 395-399, Thieme, 1. Auflage, 2016
7. **Patrick Imesch**, Edgar Petru und Daniel Fink
Maligne, nichtepitheliale Tumoren des Corpus uteri (ausschließlich des Karzinosarkoms)
In: Praxisbuch Gynäkologische Onkologie, pp ..., Springer, 5. Auflage
8. **Patrick Imesch**, Edgar Petru und Daniel Fink
Maligne epitheliale Tumoren des Corpus uteri (einschließlich des Karzinosarkoms)

Preise als Erstautor:

2008: 2nd poster award, Annual meeting of the Swiss Association for Obstetrics and Gynecology (SGGG), Jahreskongress SGGG Interlaken (Effect of Depsipeptide on angiogenic, invasive and adhesive factors in endometriosis)

2008: 2nd poster award, Annual meeting DGGG 2008 Hamburg "Effect of histone deacetylase inhibitors on angiogenic, invasive and adhesive factors in endometriosis".

2009: 1st poster award, 8th Day of Clinical Research, Zurich, April 16, 2009 "Epigenetic Regulations in Endometriosis by Histone Deacetylase Inhibitors – A Novel Therapeutic Option?"

2009: 1st lecture award, 8. Deutscher Endometriosekongress, Münster, 9.-12-9-2009

2010: Award, Bayer HealthCare Bayer Schering Pharma, 10'000.-

Preise als Co-Autor:

2005: 2nd poster award, Annual meeting of the Swiss Association for Obstetrics and Gynecology (SGGG), Lugano 6.26.-28.2005 (Histone Deacetylase Inhibitors can induce a resistance phenotype in tumor cells)

2006: 1st poster award, Annual meeting of the Swiss Association for Obstetrics and Gynecology (SGGG), Interlaken 6.22.-24.2006 (A novel property of AKT/Protein Kinase B that increases the cytotoxic effect of platinum compounds)

2009: 1st lecture award, 25es Journées d'Automne du Groupement Romand de la Société Suisse de Gynécologie Obstétrique GRSSGO (Montreux, 12.-14. September 2009) Inhibiteurs des histones désacetylases (HDAC-i): Un traitement futur de l'endométriose?'

2010: 1st poster award, Annual meeting of the Swiss Association for Obstetrics and Gynecology (SGGG), Jahreskongress SGGG Interlaken

2011: 1st poster award, 9. Endometriosekongress deutschsprachiger Länder, Emmendingen, 1.-3.6.2011

2018: 3rd poster award. 4th European Congress on Endometriosis, 22.11.-24.11 2018, Vienna The ENZIAN Score as a preoperative MRI-based classification instrument in deep infiltrating endometriosis

